Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

Table 1 Reported cases of immune-related thrombocytopenia induced by nivolumab in patients with non-small cell lung cancer

Author (reference)	Year	Age (years)/sex	Cycle	PLT lowest count	PA-IgG (ng/10⁷ cells)	Treatment	Other ir-AE	Outcome
Bagley et al. [6]	2016	34/M	8	33,000/μL	NR	TRA	None	Recovered
Karakas et al. [7]	2017	78/M	6	5000/μL	NR	S	None	Died of cancer
Jotatsu et al. [8]	2018	62/M	2	1600/μL	473	S	Hashimoto’s disease	Recovered
Tokumo et al. [9]	2018	56/F	3	19,000/μL	NR	S, I	Pancytopenia	Died of cancer
Present case	2018	82/F	2	2000/μL	223	S, I, TRA	None	Died of AE

AE adverse event, F female, I immunoglobulin, ir-AE immune-related adverse event, M male, NR not reported, PA-IgG platelet-associated immunoglobulin G, PLT platelets, S steroid therapy, TRA thrombopoietin receptor agonist

ISSN: 1752-1947